The prognosis of canine soft tissue sarcomas (STSs) primarily depends on the histopathologic grade, particularly the mitotic index. The decision to administer adjuvant chemotherapy is difficult, since less than half of patients with high grade STSs develop metastatic disease. We hypothesize that there is a gene expression signature which will improve our ability to predict development of metastatic disease in STS patients. The first step is the identification of differentially expressed genes.
展开▼
